BiVictriX Therapeutics

BiVictriX Therapeutics is a clinical-stage biotechnology company developing bispecific antibody-drug conjugates for cancer.

The platform targets pairs of cancer-specific antigens simultaneously, aiming to achieve greater cancer selectivity than conventional antibody-drug conjugates and enable higher, safer dosing.

Lead candidate BVX001 targets CD33/CD7 for acute myeloid leukaemia and has received FDA Orphan Drug Designation, with additional pipeline candidates in development for ovarian, bladder and other solid tumours.